drugset / Trial / NCT03853096

P.Acnes Colony Count Following Subdermal Cefazolin

NCT03853096

Phase 0 Unknown 20 enrolled University of British Columbia
NaSingle-groupOpen-labelPrevention

Summary

The specific outcome is to determine whether the colony count of Propionibacterium acnes, one of the commonest causes of shoulder infection and not eradicated by conventional forms of surgical preparatory solutions and antibiotics, in a shoulder surgical wound will be altered by the use of subdermal cefazolin.

Timeline

Start
2019-04-01
Primary completion
2020-04-01
Completion
2020-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefazolin Small molecule 900 mg Subcutaneous

Indications

No indication recorded.